Analysts have reiterated their previous price target for Sanara MedTech at $41.00. They cite minimal changes in key financial assumptions and maintain a stable outlook for the company.
What's in the News
- Sanara MedTech has discontinued operations of Tissue Health Plus (THP) following a completed evaluation of strategic alternatives and will reclassify THP as discontinued operations in future financial statements. (Key Developments)
- The strategic wind-down of THP is expected to continue through the end of 2025, with total cash investment estimated between $5.5 million and $6.5 million for the second half of the year. No material cash expenses for THP are expected after year-end. (Key Developments)
- Seth Yon, previously President and Chief Commercial Officer, has been named President and Chief Executive Officer, effective September 15, 2025, succeeding Ron Nixon, who remains Executive Chairman. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $41.00.
- The discount rate has decreased slightly from 8.30% to 8.28%.
- The revenue growth projection is stable, remaining at roughly 13.25%.
- The net profit margin shows a minor increase from 32.45% to 32.45%.
- The future P/E has edged down slightly from 9.76x to 9.76x.
Have other thoughts on Sanara MedTech?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.